Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| LGVN | 8-K | neutral | 3/10 | Longeveron Inc. disclosed that Dr. Nataliya Agafonova stepped down as Chief Medical Officer, effective October 14, 2026. | Oct 14, 2026 |
| IRLA | SC 13G | neutral | 4/10 | Perceptive Advisors LLC disclosed a passive 8.4% stake in IRulya Therapeutics Inc. via a Schedule 13G filing, holding 91 | Oct 14, 2026 |
| RDY | 6-K | neutral | 3/10 | Dr. Reddy's disclosed that the USFDA completed a Pre-Approval Inspection (PAI) at its FTO-9 manufacturing facility in Vi | Oct 14, 2026 |
| IBIO | SC 13G | neutral | 4/10 | Coastlands Capital LP disclosed a new 9.72% passive stake in iBio, Inc. via a Schedule 13G filed October 14, 2026, holdi | Oct 14, 2026 |
| GSK | 6-K | neutral | 1/10 | GSK filed a routine 6-K disclosing PDMR share transactions following the reinvestment of dividends paid on October 8, 20 | Oct 14, 2026 |
| SBFM | SC 13G | neutral | 3/10 | BJI Financial Group has filed a Schedule 13G disclosing a 6.0% passive stake in Sunshine Biopharma Inc., consisting of 9 | Oct 14, 2026 |
| HYFT | 6-K | neutral | 3/10 | MindWalk Holdings Corp. announced three senior appointments to its Boston-based development team as its pipeline approac | Oct 14, 2026 |
| ALVO | 6-K | bullish | 7/10 | Alvotech and Advanz Pharma announced the first known regulatory submission worldwide for AVT29, a proposed biosimilar to | Oct 14, 2026 |
| ONCY | 8-K | neutral | 3/10 | Oncolytics Biotech provided an update on its GOBLET Phase 1/2 study, announcing it expects to receive the final grant pa | Oct 14, 2026 |
| RARE | 8-K | bullish | 6/10 | Ultragenyx entered into an asset purchase agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $ | Oct 14, 2026 |
| ALEC | 8-K | neutral | 3/10 | Alector's board approved an option repricing on October 13, 2026, lowering the exercise price of approximately 4.05 mill | Oct 14, 2026 |
| APVO | 8-K | neutral | 3/10 | Aptevo announced a non-clinical scientific presentation of its multispecific CD40-directed platform at the SITC 2026 Ann | Oct 14, 2026 |
| PLSE | 8-K | neutral | 4/10 | Pulse Biosciences announced a commercial and clinical partnership with the Clayman Thyroid Center at the Hospital for En | Oct 14, 2026 |
| VIR | 8-K | bullish | 6/10 | Vir Biotechnology entered into a collaboration and license agreement with Gilead Sciences to discover and engineer three | Oct 14, 2026 |
| COYA | 8-K | mixed | 5/10 | Coya Therapeutics announced plans to initiate an open-label extension (OLE) of its Phase 2/3 ALSTARS trial for COYA 302 | Oct 14, 2026 |
| BDRX | 6-K | bullish | 6/10 | Biodexa announced enrollment of the 100th patient in its registrational Phase 3 trial (Serenta) of eRapa for Familial Ad | Oct 14, 2026 |
| CNTN | PRESS-RELEASE | neutral | 3/10 | Canton Strategic Holdings released its Q3 2026 ecosystem report highlighting governance milestones, six new Super Valida | Oct 14, 2026 |
| MXCT | 8-K | bullish | 6/10 | MaxCyte reported preliminary Q3 2026 core revenue of ~$8.1M (+26% YoY) and raised full-year 2026 revenue guidance to ~$3 | Oct 14, 2026 |
| ACTU | S-1/A | bearish | 6/10 | Actuate Therapeutics filed Pre-Effective Amendment No. 1 to its S-1 registration statement for a follow-on offering of 6 | Oct 14, 2026 |
| ONMD | 8-K | bullish | 5/10 | OneMedNet received written notice from Nasdaq on October 13, 2026 confirming it has regained compliance with the $1.00 m | Oct 14, 2026 |
| AKBA | 8-K | neutral | 3/10 | Akebia Therapeutics disclosed the resignation of Nicholas Grund, Senior Vice President and Chief Commercial Officer, eff | Oct 14, 2026 |
| TRDA | 8-K | bullish | 6/10 | Entrada Therapeutics announced positive topline data from Cohort 1 of the Phase 1/2 ELEVATE-45-201 study of ENTR-601-45 | Oct 14, 2026 |
| KPTI | 8-K | neutral | 3/10 | Karyopharm Therapeutics filed an 8-K to extend the forbearance period under its existing Forbearance Agreement and Limit | Oct 14, 2026 |
| AQST | 8-K | bullish | 6/10 | Aquestive Therapeutics granted Eton Pharmaceuticals exclusive U.S. rights to commercialize LIBERVANT (diazepam) buccal f | Oct 14, 2026 |
| ETON | 8-K | bullish | 6/10 | Eton Pharmaceuticals entered into an exclusive U.S. license and supply agreement with Aquestive Therapeutics for LIBERVA | Oct 14, 2026 |
| XERS | 8-K | neutral | 3/10 | Xeris Biopharma filed patent infringement lawsuits against Torrent Pharma, Cycle Pharmaceuticals, Rising Pharma, and rel | Oct 14, 2026 |
| UTHR | 8-K | bullish | 7/10 | United Therapeutics (UTHR) entered into a comprehensive settlement agreement with Liquidia Technologies, resolving all p | Oct 14, 2026 |
| QNRX | 8-K | bullish | 5/10 | Quoin Pharmaceuticals announced that its lead product candidate QRX003 received Orphan Drug Designation from the EMA for | Oct 14, 2026 |
| VSTM | 8-K | bullish | 7/10 | Verastem reported preliminary Q3 2026 net product revenue of ~$23.9-24.1M (vs $11.2M YoY), announced CEO Dan Paterson's | Oct 14, 2026 |
| PHAR | 6-K | bullish | 6/10 | Pharming Group N.V. announced positive Phase II topline data for leniolisib in genetic primary immunodeficiencies (PIDs) | Oct 14, 2026 |